Head-To-Head Review: TC Biopharm (NASDAQ:TCBP) versus Inhibrx (NASDAQ:INBX)

Inhibrx (NASDAQ:INBX) and TC Biopharm (NASDAQ:TCBP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Inhibrx and TC Biopharm’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	-113.74%	-80.56%
TC Biopharm	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and price targets for Inhibrx and TC Biopharm, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0	2	0	0	2.00
TC Biopharm	0	0	0	0	0.00

Earnings & Valuation

This table compares Inhibrx and TC Biopharm”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	$1.63 million	133.25	-$154.96 million	N/A	N/A
TC Biopharm	$4.76 million	0.07	-$7.35 million	N/A	N/A

TC Biopharm has higher revenue and earnings than Inhibrx.

Insider & Institutional Ownership

82.5% of Inhibrx shares are held by institutional investors. Comparatively, 16.3% of TC Biopharm shares are held by institutional investors. 15.4% of TC Biopharm shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

TC Biopharm beats Inhibrx on 5 of the 8 factors compared between the two stocks.

About Inhibrx

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.